The Role of Adjuvant Radiation in High Risk Early-Stage Endometrial CancerSareena Singh1*, Amy Armstrong1 and Analisa DiFeo2
- *Corresponding Author:
- Sareena Singh
Department of Gynecologic Oncology
University Hospitals Case Medical Center
11100 Euclid Avenue, Mailstop MAC 5034
Cleveland, OH 44106, OH, USA
E-mail: [email protected]
Received date: June 05, 2014; Accepted date July 18, 2014; Published date: July 31, 2014
Citation: Singh S, Armstrong A, DiFeo A (2014) The Role of Adjuvant Radiation in High Risk Early-Stage Endometrial Cancer. J Nucl Med Radiat Ther 5:185. doi: 10.4172/2155-9619.1000185
Copyright: © 2014 Singh S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Endometrial cancer is the most commonly diagnosed malignancy of the female genital tract in the United States. The role of adjuvant radiation for the treatment of patients with early stage disease is still heavily debated, as no overall survival benefit has been demonstrated in large prospective trials. There is, however, evidence to suggest a decrease in recurrence risk with administration of adjuvant radiotherapy, especially in patients with high-risk features. In this review, we describe the relevant literature to date, define how we determine which patients are considered high or intermediate risk, and describe the findings related to the addition of chemotherapy to adjuvant brachytherapy.